Arena Pharmaceuticals, reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ by 50% to approximately 600.
Boston Strategics Corporation has entered into an exclusive licensing and development agreement...
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate...
Eisai and Helsinn Group today announced the FDA approval of ALOXI injection for the prevention...
Otsuka Pharmaceutical Co., Ltd.has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen ® and to an enzyme inhibitor, E7727.
Eisai Inc. has announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr. Matsue and Ms. Procida succeed current President and CEO Lonnel Coats, who will be retiring from Eisai in June 2014 after 18 years.
Eisai and Biogen Idec announced have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401.
Eisai announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a ground-breaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB).
Eisai has announced that it will increase the number of sales representatives for the anti-obesity agent BELVIQ® (lorcaserin hydrochloride) by more than 200 contract employees to increase awareness and education about BELVIQ among healthcare providers.
Eisai filed litigation against the US Drug Enforcement Agency (DEA) Monday in a US Court of Appeals to compel the agency "to promptly schedule" its epilepsy drug Fycompa (perampanel), which was approved by the FDA in October last year. The drugmaker alleges the DEA "unreasonably" and "egregiously" delayed the scheduling of Fycompa, for which the FDA submitted its scheduling recommendation in January.
Arena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators. The Food and Drug Administration approved Belviq last June for adults who are obese or who are overweight and...
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels for new products, indications and life-cycle extensions.
More than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. announced today that Valeant has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones
Japanese drug maker Eisai Co. said Friday its subsidiary in Taiwan has agreed to divest its plant in southern Taiwan to Taiwanese pharmaceutical firm Bora Corp. The divestment by Eisai Taiwan Inc. of its plant in Tainan, which has served as a production base for emerging markets, particularly in Asia, is expected to be completed by September, the parent company said.
Eisai and UCL Form Major Drug Discovery Alliance to Develop New Therapeutics for Neurological DiseasesDecember 13, 2012 3:20 am | News | Comments
UCL and the Japanese pharmaceutical company Eisai, today announce the agreement to establish a major drug discovery and development collaboration.
Biogen Idec and Eisai Inc. today announced a strategic alliance that will bolster the manufacturing capabilities of both companies’ Research Triangle Park (RTP)-based facilities.
TRENTON, N.J. (AP) — A consumer group pressing the Food and Drug Administration to remove the highest dose of an Alzheimer's disease drug from the market is suing the agency for what it calls "foot-dragging."
Eisai Inc. and Arena Pharmaceuticals, Inc. announced today that Arena has transferred the BELVIQ (lorcaserin hydrochloride) New Drug Application (NDA) to Eisai.
Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku Co., Ltd., pertaining to exclusive overseas marketing rights for the Aricept patch (once weekly donepezil HCl transdermal system).
SAN DIEGO (AP) — Arena Pharmaceuticals Inc. said yesterday that the FDA will make a new ruling on its obesity drug lorcaserin by June 27.
SAN DIEGO (AP) — Arena Pharmaceuticals Inc. said yesterday it has sent regulators more information about its experimental drug lorcaserin to treat obesity.
GENEVA (AP) — Eight drug makers have agreed to create a U.N.-administered pool of patented information and other data to spur new research into 21 tropical diseases and ailments, industry and U.N. officials said Wednesday.
Eisai Inc. announced today that the company has decided to discontinue global development of rabeprazole sodium extended-release capsules, 50 mg.
The National Institute for Health and Clinical Excellence released draft guidance Wednesday, recommending against NHS reimbursement of Eisai's Halaven (eribulin) as a treatment for advanced breast cancer.
Eisai announced today that the FDA issued a Complete Response Letter to Teikoku Pharma USA, Inc., regarding the New Drug Application (NDA) of the Aricept(R) Patch (donepezil transdermal system).
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., has announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 20 percent across all U.S. functions, eliminating approximately 600 positions in total by April 1, 2011.
FDA Agrees to Special Protocol Assessment (SPA) toEvaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINVJanuary 12, 2011 3:51 am | News | Comments
Helsinn Group and Eisai Inc. announced today that the FDA has agreed to the safety and efficacy protocols for Phase III trials with an investigational oral fixed-dose combination of netupitant and palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
- Page 1